Novo Nordisk: These Bold Moves Point Toward Upside

anilakkus Investment Thesis In this article, I explore Novo Nordisk (NVO). I provide some very relevant information regarding where the company stands with product and the outlook as we begin the 2024 year. There have been major updates with Wegovy and the company’s weight loss drug market, so we will dive into each of them. Despite skepticism about the sustainability of this sector's growth, I maintain a bullish stance. The increasing demand and improved accessibility of GLP-1 drugs along with the very ...